{
    "clinical_study": {
        "@rank": "112511", 
        "arm_group": {
            "arm_group_label": "Methotrexate and Calcium folinate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "At present, the most effective drugs to osteosarcoma include ADM,DDP,,HD-MTX,IFO and so\n      on.The effective rate of single drug was about 30%, and if the chemotherapy contains HD-MTX,\n      the survival rate can reach about 60%, so the HD-MTX is the most important component in\n      patients of osteosarcoma.\n\n      Studies have shown that, MTX efficacy and adverse reactions were associated with blood\n      concentration level and duration, selecting the right time and dose to give CF is the\n      critical point."
        }, 
        "brief_title": "A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteosarcoma", 
        "condition_browse": {
            "mesh_term": "Osteosarcoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Proved by pathology in 60 cases of osteosarcoma patients\n\n          2. PS \u2264 2, survival period is more than 6 months\n\n          3. Normal function of liver and kidney\n\n          4. No chemotherapy contraindication, patients treat with high dose methotrexate\n\n          5. Get signed written informed consent form\n\n          6. Have a good compliance with take blood and follow-up\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758666", 
            "org_study_id": "CIH-WAC-201205001"
        }, 
        "intervention": {
            "arm_group_label": "Methotrexate and Calcium folinate", 
            "intervention_name": "Methotrexate,Calcium folinate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Calcium, Dietary", 
                "Leucovorin", 
                "Levoleucovorin", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 31, 2012", 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Tianjin Medical University Cancer Institute and Hospital", 
            "last_name": "Chen Wang", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "blood concentration of MTX", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758666"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "other adverse reaction", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 years"
        }, 
        "source": "Tianjin Medical University Cancer Institute and Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}